Molecular diagnostics company Mobidiag has received an EIB loan to accelerate the development and commercialisation of its in vitro diagnostic solutions for infectious diseases.
ADVERTISEMENT
Privately financed Italian antibody-cytokine fusion protein specialist Philogen SpA has secured €62m from private investors including the Neri and Dompé families to push registration of two wholly owned Phase III products.
Immunocore has appointed Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer. Mohammed Dar will lead the continued clinical development of tebentafusp(IMCgp100) and other key programmes in Immunocores pipeline.
Roche had a nose for success when the pharma giant ended the CHF500m deal with Polyphor in November 2015. Now, the antibiotics maker stopped a Phase III trial of its lead murepavadin (Pol7080).
Medica Group Plc (LSE:MGP) announces that Dr Stuart Quin has been appointed as Chief Executive Officer. Dr Quin will join Medica and its Board of Directors on 1 September 2019. John Graham will remain as Chief Executive Officer until Dr Quin joins the company.
Following the birth of genome-edited twins in China, the German Ethics Council has provided a complete ethical review about human germline intervention.
Epigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment.
Oncology drugs developed through a biomarker-guided precision medicine design are 38% more likely to be commercialized. But success relies on following a plan from the start — learn how in this free whitepaper
With partner Indivior exchanging a late-stage addiction programme for early-stage alternatives, 2019 did not start exceptionally well for Addex Therapeutics. But, the Swiss drug developer has shown the stamina to withstand far more serious setbacks in the past. For EuroBiotech, Addexs CEO Tim Dyer recounts the companys history and outlines its future.